The CMT Research Foundation is a non-profit organization based in Atlanta, Georgia, established in 2018. It is dedicated to advancing research aimed at developing treatments and cures for Charcot-Marie-Tooth disease, a hereditary neurological disorder. The foundation is patient-led, prioritizing the needs and experiences of those affected by CMT in its research initiatives. Through its focus on innovative approaches and collaboration with researchers, the foundation seeks to achieve meaningful outcomes in the fight against this condition. The executive management team oversees the foundation's operations, ensuring that its mission to improve the lives of individuals with CMT remains at the forefront of its efforts.
Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.
ReviR Therapeutics
Series A in 2024
ReviR Therapeutics is a genomics-focused company that develops innovative RNA-based medicines aimed at treating cancer, rare genetic disorders, and infectious diseases. The company leverages an artificial intelligence-driven platform to enhance the discovery of therapeutics that target human RNAs. By combining advanced computational techniques with genomic insights, ReviR Therapeutics strives to create transformative therapies that can significantly impact patient care and improve health outcomes for millions.
Asha Therapeutics
Asha Therapeutics is focused on developing innovative treatments for neurodegenerative diseases such as Parkinson’s Disease, Alzheimer’s Disease, Myalgic Encephalomyelitis, and Chronic Fatigue Syndrome. The company employs a mito-centric approach, aiming to restore cellular function by re-engineering the cellular machinery. Utilizing its proprietary PRISM™ technology, Asha Therapeutics engages in the rational design and development of novel small molecule drugs, targeting not only neurological disorders but also cancer and infectious diseases. Several of its promising candidates are progressing toward clinical trials, positioning the company at the forefront of drug discovery aimed at enhancing neurological function.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.